Stonepine Capital Management LLC Has $653,000 Holdings in Exagen Inc. (NASDAQ:XGN)

Stonepine Capital Management LLC trimmed its position in shares of Exagen Inc. (NASDAQ:XGN) by 6.7% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 358,697 shares of the company’s stock after selling 25,903 shares during the period. Exagen accounts for approximately 0.6% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 19th biggest position. Stonepine Capital Management LLC owned approximately 2.06% of Exagen worth $653,000 at the end of the most recent reporting period.

Separately, RTW Investments LP raised its stake in Exagen by 0.8% in the fourth quarter. RTW Investments LP now owns 1,504,602 shares of the company’s stock valued at $2,994,000 after buying an additional 12,170 shares during the period. Hedge funds and other institutional investors own 75.25% of the company’s stock.

Exagen Stock Performance

XGN opened at $3.09 on Tuesday. The company has a quick ratio of 4.32, a current ratio of 4.32 and a debt-to-equity ratio of 1.13. The stock has a market cap of $53.74 million, a price-to-earnings ratio of -2.83 and a beta of 1.32. Exagen Inc. has a 12-month low of $1.30 and a 12-month high of $3.71. The business has a 50 day moving average of $2.80 and a 200-day moving average of $2.10.

Exagen (NASDAQ:XGN) last released its quarterly earnings data on Monday, August 5th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.20. The firm had revenue of $15.06 million for the quarter, compared to the consensus estimate of $13.20 million. Exagen had a negative net margin of 30.56% and a negative return on equity of 78.90%. During the same period in the previous year, the company earned ($0.28) earnings per share. On average, equities research analysts expect that Exagen Inc. will post -1.02 earnings per share for the current year.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).